Abstract
Previous studies showed the reduction of dopamine transporter immunoreactivity (DAT-IR) in peripheral blood lymphocytes (PBL) in Parkinson’s disease. Here we report the reduction of DAT-IR in PBL in the extrapyramidal variant of multiple system atrophy. These results suggest the reduction of DAT-IR in PBL in a variety of neurodegenerative disorders, provided the presence of damage of the central dopaminergic systems. The reduction of DAT-IR in PBL in these disorders may represent a compensatory phenomenon aimed at reducing intracellular dopamine influx and, consequently, dopamine-mediated aggravation of oxidative stress in these cells.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Amenta F, Bronzetti E, Felici L et al (1999) Dopamine D2-like receptors on human peripheral blood lymphocytes: a radioligand binding assay and immunocytochemical study. J Auton Pharmacol 19:151–159
Amenta F, Bronzetti E, Cantalamessa F et al (2001) Identification of dopamine plasma membrane and vesicular transporters in human peripheral blood lymphocytes. J Neuroimmunol 117:133–142
Bannon MJ, Whitty CJ (1997) Age-related and regional differences in dopamine transporter mRNA expression in human midbrain. Neurology 48:969–977
Barroso N, Campos Y, Huertas R et al (1993) Respiratory chain enzyme activities in lymphocytes from untreated patients with Parkinson’s disease. Clin Chem 39:667–669
Battisti C, Formichi P, Radi E et al (2008) Oxidative stress-induced apoptosis in PBLs of two patients with Parkinson’s disease secondary to alpha-synuclein mutation. J Neurol Sci 268:183–186
Benamer TS, Patterson J, Grosset DG et al (2000) Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT Study Group. Mov Disord 15:503–510
Bergquist J, Tarkowski A, Ekman R et al (1994) Discovery of endogenous catecholamines in lymphocytes and evidence for catecholamine regulation of lymphocyte function via an autocrine loop. Proc Natl Acad Sci USA 91:12912–12916
Blandini F, Cosentino M, Mangiagalli A et al (2004) Modifications of apoptosis-related protein levels in lymphocytes of patients with Parkinson’s disease. The effects of dopaminergic treatment. J Neural Transm 111:1017–1030
Blandini F, Sinforiani E, Pacchetti C et al (2006) Peripheral proteasome and caspase activity in Parkinson disease and Alzheimer disease. Neurology 66:529–534
Borasio GD, Linke R, Schwarz J et al (1998) Dopaminergic deficit in amyotrophic lateral sclerosis assessed with [I–123] IPT single photon emission computed tomography. J Neurol Neurosurg Psychiatry 65:263–265
Brooks DJ, Frey KA, Marek KL et al (2003) Assessment of neuroimaging techniques as biomarkers of progression of Parkinson’s disease. Exp Neurol 184(suppl. 1):S78–S89
Buttarelli FR, Circella A, Pellicano C et al (2006) Dopamine transporter immunoreactivity in peripheral blood lymphocytes in amyotrophic lateral sclerosis. Eur J Neurol 13:416–418
Buttarelli FR, Capriotti G, Pellicano C et al. (2008) Central and peripheral dopamine transporter reduction in Parkinson’s disease. Neurol Res (in press)
Caronti B, Antonini G, Calderaro C et al (2001) Dopamine transporter immunoreactivity in peripheral blood lymphocytes in Parkinson’s disease. J Neural Transm 108:803–807
Caronti B, Tanda G, Colosimo C et al (1999) Reduced dopamine in peripheral blood lymphocytes in Parkinson’s disease. Neuroreport 10:2907–2910
Hughes AJ, Daniel SE, Kilford L et al (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181–184
Gilman S, Low PA, Quinn N et al (1999) Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci 163:94–98
Jimenez Del Rio M, Velez-Pardo C (2000) 17 beta-Estradiol protects lymphocytes against dopamine and iron-induced apoptosis by a genomic-independent mechanism. Implication in Parkinson’s disease. Gen Pharmacol 35:1–9
Kim S, Jeon BS, Heo C et al (2004) Alpha-synuclein induces apoptosis by altered expression in human peripheral lymphocyte in Parkinson’s disease. FASEB J 18:1615–1617
Marazziti D, Baroni S, Catena Dell’Osso M et al (2008) Presence and characterization of the dopamine transporter in human resting lymphocytes. Neurochem Res 33:1011–1016
Migliore L, Petrozzi L, Lucetti C et al (2002) Oxidative damage and cytogenetic analysis in leukocytes of Parkinson’s disease patients. Neurology 58:809–815
Pellicano C, Buttarelli FR, Circella A et al (2007) Dopamine transporter immunoreactivity in peripheral blood lymphocytes discriminates Parkinson’s disease from essential tremor. J Neural Transm 114:935–938
Petrozzi L, Lucetti C, Gambaccini G et al (2001) Cytogenetic analysis of oxidative damage in lymphocytes of Parkinson’s disease patients. Neurol Sci 22:83–84
Ricci A, Bronzetti E, Mignini F et al (1999) Dopamine D1-like receptor subtypes in human peripheral blood lymphocytes. J Neuroimmunol 96:234–240
Seeberger LC, Hauser RA (2007) Optimizing bioavailability in the treatment of Parkinson’s disease. Neuropharmacology 53:791–800
Uhl GR (1998) Hypothesis: the role of dopaminergic transporters in selective vulnerability of cells in Parkinson’s disease. Ann Neurol 43:555–560
Wenning GK, Colosimo C, Geser F et al (2004) Multiple system atrophy. Lancet Neurol 3:93–103
Acknowledgments
Supported by grants from MIUR to Francesco E. Pontieri.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Buttarelli, F.R., Circella, A., Pellicano, C. et al. Dopamine transporter immunoreactivity in peripheral blood lymphocytes in multiple system atrophy. J Neural Transm 116, 161–165 (2009). https://doi.org/10.1007/s00702-008-0170-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00702-008-0170-0